Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update

LIVONIA, Mich., May 09, 2017 (GLOBE NEWSWIRE) — Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and NASH, today announced financial results for the first quarter ended March 31, 2017, and provided a corporate update.